Summary

According to a multicenter, prospective registry study, uninterrupted apixaban used in the periprocedural setting of radiofrequency catheter ablation in patients with atrial fibrillation does not increase the risk of bleeding compared with uninterrupted warfarin. In addition, uninterrupted periprocedural apixaban is effective in preventing thromboembolism.